EP3026044A1 — Prolyl hydroxylase inhibitors and methods of use
Assigned to Akebia Therapeutics Inc · Expires 2016-06-01 · 10y expired
What this patent protects
The present invention provides a compound having the formula (I): wherein R is selected from 2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl; R 6 is hydrogen, methyl, or ethyl; or a pharmaceutically acceptable salt thereof and pharmaceutical compositions comprising the comp…
USPTO Abstract
The present invention provides a compound having the formula (I): wherein R is selected from 2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl; R 6 is hydrogen, methyl, or ethyl; or a pharmaceutically acceptable salt thereof and pharmaceutical compositions comprising the compound of formula (I) and one or more excipients. The compound is for use in methods for treating or preventing anemia, for treating anemia associated with kidney failure, for treating anemia associated with chemotherapy, for treating wounds, for regulating angiogenesis in a human, for vascularizing ischemic tissue in a human, for promoting the growth of skin graft replacements in a human, for promoting tissue repair in the context of guided tissue regeneration, and for treating or preventing cancer.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.